标题
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 2, Pages 287-295
出版商
Informa Healthcare
发表日期
2010-12-31
DOI
10.1517/13543784.2011.542750
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
- (2017) L. R. Silverman et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
- (2010) Margaret A. Park et al. CANCER BIOLOGY & THERAPY
- HDAC inhibitors conquer polycomb proteins
- (2010) Paul Yaswen CELL CYCLE
- Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity
- (2010) Chanaz Salmi-Smail et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities
- (2009) Konstantin J. Dedes et al. ANTI-CANCER DRUGS
- Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells
- (2009) C. P. Miller et al. BLOOD
- How I treat patients with myelodysplastic syndromes
- (2009) R. M. Stone BLOOD
- HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells
- (2009) C. Urbich et al. BLOOD
- Quantitative DNA methylation predicts survival in adult acute myeloid leukemia
- (2009) L. Bullinger et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
- (2009) D. Mahalingam et al. CLINICAL CANCER RESEARCH
- Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
- (2009) D. S. Schrump CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
- (2009) H. Reikvam et al. CURRENT CANCER DRUG TARGETS
- A phase 2 study of vorinostat in acute myeloid leukemia
- (2009) E. W. Schaefer et al. HAEMATOLOGICA
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells
- (2008) W. Fiskus et al. BLOOD
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
- (2008) G. Garcia-Manero et al. BLOOD
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
- (2008) Y. Jiang et al. BLOOD
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- HDAC inhibitors in leukemia: Current status and perspectives
- (2008) Gregory Kouraklis LEUKEMIA RESEARCH
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
- New Drugs in Acute Myeloid Leukemia
- (2008) Elihu Estey SEMINARS IN ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started